Clinical Scorecard: Cholinergic System Degeneration in Early and Prodromal Stages of Parkinson’s Disease: Implications for Current and Future Disease Progression
At a Glance
Category
Detail
Condition
Parkinson’s disease and prodromal Lewy body disorders
Key Mechanisms
Degeneration of the nucleus basalis of Meynert (NbM) leading to cholinergic deficits affecting cognitive and motor functions
Target Population
Non-demented early Parkinson’s disease patients and individuals with isolated REM sleep behaviour disorder (iRBD)
Care Setting
Neurology and movement disorder clinics with access to neuroimaging for biomarker assessment
Key Highlights
Significantly reduced NbM grey matter volume observed in early PD and iRBD compared to controls.
Higher NbM volume correlates with better cognitive function, lower motor and non-motor symptom burden, and reduced risk of dementia conversion in PD.
NbM volume deficits in iRBD predict future phenoconversion to PD or dementia with Lewy bodies, despite less pronounced current clinical symptoms.
Guideline-Based Recommendations
Diagnosis
Utilize structural MRI to assess NbM grey matter volume as a biomarker for early cholinergic degeneration in PD and prodromal stages.
Consider iRBD diagnosis as a strong prodromal marker for Lewy body disorders.
Management
Monitor cognitive and motor symptoms closely in early PD patients with reduced NbM volume.
Target cholinergic system dysfunction in therapeutic strategies to potentially delay cognitive decline.
Monitoring & Follow-up
Longitudinal neuroimaging to track NbM volume changes for prognostication of disease progression and dementia risk.
Regular cognitive assessments focusing on higher-order functions such as executive function, attention, and visuospatial skills.
Risks
High risk of dementia development in PD patients with low NbM volume.
In iRBD patients, reduced NbM volume indicates increased risk of phenoconversion to PD or dementia with Lewy bodies.
Patient & Prescribing Data
Early Parkinson’s disease patients and individuals with isolated REM sleep behaviour disorder without dementia
Cholinergic system integrity may guide prognosis and therapeutic targeting; however, compensatory mechanisms in prodromal stages may mask clinical symptoms despite structural deficits.
Clinical Best Practices
Incorporate NbM volume assessment via MRI in early PD and iRBD patients to identify those at higher risk for cognitive decline.
Implement comprehensive cognitive testing focusing on domains affected by cholinergic dysfunction.
Recognize iRBD as a critical prodromal marker warranting close clinical and imaging follow-up.
Consider early intervention strategies targeting cholinergic pathways to potentially modify disease progression.
by Tamir Eisenstein, Karolien Groenewald, Ludo van Hillegondsberg, Falah Al Hajraf, Tanja Zerenner, Michael A Lawton, Yoav Ben-Shlomo, Ludovica Griffanti, Michele T Hu, Johannes C Klein
Aviva Abosch, M.D., Ph.D., a neurosurgeon at Baptist Health Miami Neuroscience Institute, part of Baptist Health Brain and Spine Care, was installed as the Esernia Endowed Chair in Surgical Treatment of Adult Epilepsy and Movement Disorders.
